Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MMR immunogenicity and safety in infants vaccinated at 8 versus 18 months
ChiCTR1800019079Phase 4Completed
- Sponsor
- Chinese Center for Disease Control and Prevention
- Start
- Dec 2016
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of M-M-R II and Measles and Rubella Vaccine (PT Bio Farma) in measles, mumps and rubella (2 arms), sponsored by Chinese Center for Disease Control and Prevention. Primary endpoints: Measles IgG antibody level, Rubella IgG antibody level and 1 more. Started Dec 2016; status: completed.
02
Drugs
M-M-R IIMeasles and Rubella Vaccine (PT Bio Farma)
03
Conditions
measlesmumpsrubella
Beyond the preview
Go deeper on ChiCTR1800019079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019079.